RRM2 and hepatocellular carcinoma: In summary, our study suggests that RRM2 is a potential therapeutic target for HCC, as its downregulation through CRISPR/Cas9 disrupts multiple signaling pathways in HepG2 cells, leading to reduced proliferation, impaired migration and induced cell cycle arrest and apoptosis.